Sage Therapeutics, Biogen Sees Positive Results for Essential Tremors Treatment
April 12 2021 - 7:53AM
Dow Jones News
By Chris Wack
Sage Therapeutics Inc. and Biogen Inc. said they saw positive
topline results from a Phase 2 study evaluating SAGE-324 in the
treatment of people with essential tremor.
The companies said the study achieved its primary endpoint of a
statistically significant reduction from baseline compared to
placebo in the Essential Tremor Rating Assessment Scale upper limb
tremor score on day 29.
Activities of daily living scores showed a statistically
significant correlation with upper limb tremor score at all
timepoints. SAGE-324 was numerically superior to placebo at all
time points. Reported treatment-emergent adverse events were
generally consistent with the safety profile of SAGE-324 to
date.
The companies are planning next steps for development of
SAGE-324.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 12, 2021 07:38 ET (11:38 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2024 to May 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From May 2023 to May 2024
